We are live on ! Find out more

776 hedge funds and large institutions have $66.2B invested in Biogen in 2014 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 283 increasing their positions, 295 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

102% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 47

9% more capital invested

Capital invested by funds: $61B → $66.2B (+$5.27B)

5% more funds holding

Funds holding: 739776 (+37)

4% less repeat investments, than reductions

Existing positions increased: 283 | Existing positions reduced: 295

11% less funds holding in top 10

Funds holding in top 10: 3733 (-4)

25% less call options, than puts

Call options by funds: $897M | Put options by funds: $1.2B

Holders
776
Holders Change
+37
Holders Change %
+5.01%
% of All Funds
22.33%
Holding in Top 10
33
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-10.81%
% of All Funds
0.95%
New
95
Increased
283
Reduced
295
Closed
47
Calls
$897M
Puts
$1.2B
Net Calls
-$304M
Net Calls Change
-$446M

BIIB Hedge Fund Activity: Q1 2014 in Review

776 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2014, worth a combined $66.2B — up 8.6% from $61B a quarter earlier.

Buyers outnumbered sellers: 95 funds opened new BIIB positions and 47 closed out — a net gain of 48 holders — while 283 added to existing stakes and 295 trimmed.

The largest buyer was Janus Henderson Investors US, adding an estimated $257M. The largest seller was Fidelity Investments, cutting an estimated $672M.

  • 776 institutional investors held Biogen (BIIB) as of Q1 2014, up from 739 in Q4 2013.
  • Funds reported $66.2B of Biogen stock for Q1 2014, up 8.6% quarter-over-quarter.
  • 95 funds opened new Biogen positions in Q1 2014 and 47 closed out, a net change of +48 holders.
  • The largest Biogen buyer in Q1 2014 was Janus Henderson Investors US, an estimated $257M added.
  • The largest Biogen seller in Q1 2014 was Fidelity Investments, an estimated $672M sold.

Based on aggregated 13F filings for Q1 2014.